Retention in Telehealth-Delivered Buprenorphine Treatment for Opioid Use Disorder: A Multistate Retrospective Cohort Study.

Laura B Monico¹, Elizabeth A Bambury², Jennifer K Foreman¹, Melody Avila¹, Stephen A Martin¹

¹Boulder Care, 111 SW Naito ParkwaySuite 200, Portland, US.

²Boulder Care, Portland, US.

Abstract

BACKGROUND: Buprenorphine is an effective treatment for opioid use disorder and is associated with reduced mortality when retention is high, yet national studies show low retention. Evidence from outpatient settings such as telehealth remains limited, despite population-level analyses suggesting improved retention with virtual care. Further research is needed to better understand retention and opt…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.